Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The tumour suppressor p53 is frequently mutated in tumours. Mutant p53 (Mutp53) proteins often gain new activities in promoting tumorigenesis, defined as gain-of-function (GOF). Mutp53 can accumulate to high levels in tumours, which promotes mutp53 GOF in tumorigenesis. The mechanism of mutp53 accumulation is poorly understood. Here we find that MDM2 isoforms promote mutp53 accumulation in tumours. MDM2 isoform B (MDM2-B), the MDM2 isoform most frequently over-expressed in human tumours, interacts with full-length MDM2 to inhibit MDM2-mediated mutp53 degradation, promoting mutp53 accumulation and GOF in tumorigenesis. Furthermore, MDM2-B overexpression correlates with mutp53 accumulation in human tumours. In mutp53 knock-in mice, a MDM2 isoform similar to human MDM2-B is overexpressed in the majority of tumours, which promotes mutp53 accumulation and tumorigenesis. Thus, overexpression of MDM2 isoforms promotes mutp53 accumulation in tumours, contributing to mutp53 GOF in tumorigenesis. This may be an important mechanism by which MDM2 isoforms promote tumorigenesis. Mdm2 controls the levels of the tumour suppressor p53 in cells and p53 is often mutated in cancer. Here, Zheng et al. show that a particular Mdm2 isoform that is altered in cancer leads to elevated levels of mutant p53 protein and enhanced gain-of-function of the protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
Chen, X., Ko, L. J., Jayaraman, L., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.19.2438 · Cited by 735
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
Wang, S.-P., Wang, W.-L., Chang, Y.-L., Wu, C.-T., Chao, Y.-C., Kao, S.-H., Yuan, A., Lin, C.-W., Yang, S.-C., Chan, W.-K., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1875 · Cited by 493
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect
Zhang, C., Lin, M., Wu, R., Wang, X., Yang, B., Levine, A. J., Hu, W., & Feng, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113884108 · Cited by 431
Self-citationLi, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Ubiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
ATM activates p53 by regulating MDM2 oligomerization and E3 processivity
Cheng, Q., Chen, L., Li, Z., Lane, W. S., & Chen, J. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.294 · Cited by 165
An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis
Steinman, H. A., Burstein, E., Lengner, C., Gosselin, J., Pihan, G., Duckett, C. S., & Jones, S. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305966200 · Cited by 96
Research works printed but not linked: 27
- Levine, A. J., Hu, W. & Feng, Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 13, 1027–1036 (2006). · DOI · Paper page
- Blandino, G., Levine, A. J. & Oren, M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18, 477–485 (1999). · DOI · Paper page
- Midgley, C. A. & Lane, D. P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15, 1179–1189 (1997). · DOI · Paper page
- Terzian, T. et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 1337–1344 (2008). · DOI · Paper page
- Bartel, F. et al. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer 95, 168–175 (2001). · DOI · Paper page
- Matsumoto, R. et al. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58, 609–613 (1998).
- Bartel, F., Harris, L. C., Wurl, P. & Taubert, H. MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides. Mol. Cancer Res. 2, 29–35 (2004). · DOI · Paper page
- Bartel, F., Taubert, H. & Harris, L. C. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2, 9–15 (2002). · DOI · Paper page
- Fridman, J. S. et al. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res. 63, 5703–5706 (2003).
- Schuster, K., Fan, L. & Harris, L. C. MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal. Mol. Cancer Res. 5, 403–412 (2007). · DOI
- Evans, S. C. et al. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20, 4041–4049 (2001). · DOI
- Dang, J. et al. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 62, 1222–1230 (2002).
- Cheng, Q. et al. Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage. Mol. Cell Biol. 31, 4951–4963 (2011). · DOI · Paper page
- Duan, W., Gao, L., Jin, D., Otterson, G. A. & Villalona-Calero, M. A. Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice. Transgenic Res. 17, 355–366 (2008). · DOI
- Scian, M. J. et al. Modulation of gene expression by tumour-derived p53 mutants. Cancer Res. 64, 7447–7454 (2004). · DOI · Paper page
- Adorno, M. et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87–98 (2009). · DOI · Paper page
- Strano, S. et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275, 29503–29512 (2000). · DOI · Paper page
- Liu, J. et al. TAp63gamma enhances nucleotide excision repair through transcriptional regulation of DNA repair genes. DNA Repair (Amst.) 11, 167–176 (2012). · DOI
- Di Como, C. J., Gaiddon, C. & Prives, C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell Biol. 19, 1438–1449 (1999). · DOI · Paper page
- Chandler, D. S., Singh, R. K., Caldwell, L. C., Bitler, J. L. & Lozano, G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 66, 9502–9508 (2006). · DOI · Paper page
- Muller, P., Hrstka, R., Coomber, D., Lane, D. P. & Vojtesek, B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 27, 3371–3383 (2008). · DOI · Paper page
- Esser, C., Scheffner, M. & Hohfeld, J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 280, 27443–27448 (2005). · DOI · Paper page
- Li, D. et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 9, 577–588 (2011). · DOI · Paper page
- Suh, Y. A. et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 71, 7168–7175 (2011). · DOI · Paper page
- Harvey, D. M. & Levine, A. J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5, 2375–2385 (1991). · DOI · Paper page
- Chen, J., Marechal, V. & Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13, 4107–4114 (1993). · DOI · Paper page
- Hu, W. et al. Gene Amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 1, 360–368 (2010). · DOI
Cited by
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
Self-citationMutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
Self-citationTumor suppressor p53 and metabolism
Liu, J., Zhang, C., Hu, W., & Feng, Z. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy070 · Cited by 300
Self-citationRole of p53 circuitry in tumorigenesis: A brief review
Niazi, S., Purohit, M., & Niazi, J. H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.099 · Cited by 65
Metadata
- Authors
- Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, W.
- Venue
- Nature Communications
- Published
- 2013-12-20
- Volume
- 4
- Issue
- 1
- Pages
- 2996-2996
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2094042239
- Cited by
- 108
- References
- 15
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.